GLP1R gene variants are associated with cardiometabolic traits and behavioral changes, but findings suggest that the behavioral effects of GLP1RA are indirect
In a study published in DiabetesObesity and Metabolismresearchers investigated how genetic variants of GLP1R affect mental illness and cardiometabolic traits, shedding light on the behavioral effects of GLP1RA.
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for type 2 diabetes and obesity, are gaining attention for their potential effects beyond weight loss. Mental health disorders often overlap with metabolic diseases, with studies showing links between obesity, depression and common biological pathways.
Emerging evidence suggests that GLP-1 RAs may affect mental health and behavior, including reducing addictive behaviors such as smoking and alcohol abuse. While their metabolic benefits—such as improved blood glucose control, reduced body fat, and reduced inflammation—are well documented, the behavioral effects remain unclear.
Research shows mixed results: some studies report protective or neutral effects on mental health, while others suggest adverse effects. Further research is needed to clarify these findings and guide their use in patients with both metabolic and mental health conditions.
The study
The scientists analyzed common genetic variants in the GLP1R gene in 408,774 white British, 50,314 white Europeans, 7,667 from South Asia, 10,437 of multiple ancestry and 7,641 people from Africa and the Caribbean.
The study found consistent associations between GLP1R gene variants and cardiometabolic traits, including body mass index (BMI), blood pressure and type 2 diabetes, across all origins.
Significant associations were also observed between GLP1R variants and behavioral traits in all ancestries except South Asian ancestry. Specifically, these associations were observed for risk-taking behavior, mood instability, chronic pain, and anxiety.
Meta-analysis of transparental ancestry showed consistent effects of GLP1R on cardiometabolic traits across ancestries, but inconsistent effects on behavioral traits.
Specifically, the study found that GLP1R variants affecting cardiometabolic traits were distinct from those affecting behavioral traits.
Seven lead variants showed associations with behavioral traits. However, none of these variants affected GLP1R gene expression levels, suggesting that the effects of GLP1R variants on behavioral traits are unlikely to occur through GLP1R.
The study was unable to find any significant positive or negative effects of GLP1RA on behavioral changes. These observations collectively suggest that GLP1RA, as an obesity and diabetes drug, is unlikely to cause depression or other serious mental health disorders via the GLP1R.
“Although it is not possible to directly compare the genetic findings with the effects of a drug, our results suggest that behavioral changes are unlikely to be a direct result of GLPRAs. Exactly how these indirect effects occur is currently unclear,” said Rona J. Strawbridge, the corresponding author and a scientist at the University of Glasgow in the United Kingdom.
Importance of study
The study provides valuable insights into the genetic architecture of the GLP1R locus and its associations with cardiometabolic and psychiatric traits.
The study’s findings suggest that GLP1R variants affect these traits in different ancestors without directly mediating behavioral changes through GLP1R. Considering these observations, the scientists suggest that GLP1RA therapies may be widely used in patients with type 2 diabetes and obesity without undue concern about an increase in mental health problems.
However, the scientists emphasize the need for long-term randomized controlled trials and pharmaco-epidemiological datasets to more conclusively understand the mental health and behavioral effects of GLP1RA.
